Gallium-68 is a positron-emitting nuclide that has recently achieved clinical acceptance as the diagnostic radionuclide in PET tracers used for theranostic studies of lutetium-177 labeled therapeutic drugs due to the ease of access provided by germanium-68/gallium-68 generators. An alternative method of production currently being explored uses accelerators to form gallium-68 directly. This review of gallium-68 production strategies discusses available accelerator targetry at a range of beam energies and intensities, the many radiochemical separation techniques available to isolate Ga-68 from irradiated targets, isotopically enriched target material recovery, and the implications of these techniques for downstream radiolabeling applications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1874471013666201224113651 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Review of Accelerator-Produced Ga-68 with Solid Targets.
Curr Radiopharm
December 2021
Department of Medical Physics and Radiology, University of Wisconsin-Madison B1303 WIMR Cyclotron Laboratory, 1111 Highland Avenue, Madison WI 53705, United States.
Gallium-68 is a positron-emitting nuclide that has recently achieved clinical acceptance as the diagnostic radionuclide in PET tracers used for theranostic studies of lutetium-177 labeled therapeutic drugs due to the ease of access provided by germanium-68/gallium-68 generators. An alternative method of production currently being explored uses accelerators to form gallium-68 directly. This review of gallium-68 production strategies discusses available accelerator targetry at a range of beam energies and intensities, the many radiochemical separation techniques available to isolate Ga-68 from irradiated targets, isotopically enriched target material recovery, and the implications of these techniques for downstream radiolabeling applications.
View Article and Find Full Text PDFThe 20th Gray lecture 2019: health and heavy ions.
Br J Radiol
November 2020
Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Objective: Particle radiobiology has contributed new understanding of radiation safety and underlying mechanisms of action to radiation oncology for the treatment of cancer, and to planning of radiation protection for space travel. This manuscript will highlight the significance of precise physical and biologically effective dosimetry to this translational research for the benefit of human health.This review provides a brief snapshot of the evolving scientific basis for, and the complex current global status, and remaining challenges of hadron therapy for the treatment of cancer.
View Article and Find Full Text PDF68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals.
Contrast Media Mol Imaging
June 2008
Division of Radiological Chemistry, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.
PET (positron emission tomography) is a powerful diagnostic and imaging technique which requires short-lived positron emitting isotopes. The most commonly used are accelerator-produced (11)C and (18)F. An alternative is the use of metallic positron emitters.
View Article and Find Full Text PDF68Ga-PET radiopharmacy: A generator-based alternative to 18F-radiopharmacy.
Ernst Schering Res Found Workshop
February 2007
Division of Radiological Chemistry, University Hospital Basel, Switzerland.
Positron emission tomography (PET) is becoming a dominating method in the field of molecular imaging. Most commonly used radionuclides are accelerator produced 11C and 18F. An alternative method to label biomolecules is the use of metallic positron emitters; among them 68Ga is the most promising as it can be produced from a generator system consisting of an inorganic or organic matrix immobilizing the parent radionuclide 68Ge.
View Article and Find Full Text PDF(68)Ga-labeled peptides in tumor imaging.
J Nucl Med
January 2005
Division of Radiological Chemistry, Department of Radiology, University Hospital Basel, Basel, Switzerland.
Unlabelled: Radiolabeled peptides are of increasing interest in nuclear oncology. Special emphasis has been given to the development of peptides labeled with positron emitters. Among these, (68)Ga deserves special attention, because it is available from an inhouse generator rendering (68)Ga radiopharmacy independent of an onsite cyclotron.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!